The Value of the Innovative Pharmaceutical Industry – A Report Summary
This summary of a study by Deloitte combines a traditional economic impact analysis with targeted assessments of health system impacts […]
Resources
IMC breaks down and analyzes key developments in the life sciences sector for our members, policy influencers, and Canadians.
Here, you’ll find IMC’s latest press releases, reports, policy papers, infographics, and other resources on the issues shaping our industry.
ANALYSIS & REPORTS
2025 COST DRIVERS REPORT
The private drug insurance market in Canada saw a 7.3% total cost growth in 2023-2024, primarily driven by increased utilization which accounted for 60% of total cost growth. The number of claimants rose by 3.5%, with claimants making
0.9% more claims.
INFOGRAPHICS & DATA
Canadian Drug Access Pathway
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (736 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Canadian Public Reimbursement Timelines
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
Pharma 101
Use this beginner’s guide to understand the basics of how our industry works.
Advocacy
Everything you need to make an informed decision about our industry.
Newsroom
Breaking down key developments in the life sciences sector for members, policy influencers, and Canadians.
